ABCB1 polymorphism in clopidogrel-treated Montenegrin patients

Clopidogrel is an antiplatelet drug that displays significant interindividual variability in treatment response. Its bioavailability depends on the function of P-glycoprotein (P-gp), which is coded by a highly polymorphic ABCB1 gene. Thus, the aim of this study was to investigate the effect of ABCB1...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mugosa Snezana, Todorovic Zoran, Cukic Jelena, Sahman-Zaimovic Majda, Djordjevic Natasa
Formato:	article
Lenguaje:	EN
Publicado:	De Gruyter 2021
Materias:	abcb1 p-glycoprotein clopidogrel single nucleotide polymorphism Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/18aa7aa0caa3424b824c163bf3689988
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:18aa7aa0caa3424b824c163bf3689988
record_format	dspace
spelling	oai:doaj.org-article:18aa7aa0caa3424b824c163bf36899882021-12-05T14:10:40ZABCB1 polymorphism in clopidogrel-treated Montenegrin patients2391-541210.1515/biol-2021-0017https://doaj.org/article/18aa7aa0caa3424b824c163bf36899882021-02-01T00:00:00Zhttps://doi.org/10.1515/biol-2021-0017https://doaj.org/toc/2391-5412Clopidogrel is an antiplatelet drug that displays significant interindividual variability in treatment response. Its bioavailability depends on the function of P-glycoprotein (P-gp), which is coded by a highly polymorphic ABCB1 gene. Thus, the aim of this study was to investigate the effect of ABCB1 genetic polymorphism on clopidogrel efficacy and safety and to determine the frequency distribution of its most common single nucleotide polymorphisms (SNPs) in 106 Montenegrin cardiology patients. Clopidogrel efficacy and safety were followed up during 1 year after hospitalization, with the lack of efficacy and adverse drug reactions observed in 11 (10.4%) and 8 patients (7.5%), respectively. Genotyping for ABCB1 SNPs rs1128503 (1236C > T), rs2032582 (2677G > A/T), and rs1045642 (3435C > T) was performed by the real-time PCR method, and the variant alleles were detected with the frequencies of 42.9, 44.8, and 52.8%, respectively. No significant association was observed between any of the examined genotypes and clopidogrel efficacy (p = 0.253) or safety (p = 0.424). Due to small sample size, co-treatment with other drugs, and other genetic factors not taken into account, we believe the absence of correlation between ABCB1 genotypes and indicators of clopidogrel efficacy and safety in this study should be apprehended conditionally, and that larger and better-controlled studies are warranted.Mugosa SnezanaTodorovic ZoranCukic JelenaSahman-Zaimovic MajdaDjordjevic NatasaDe Gruyterarticleabcb1p-glycoproteinclopidogrelsingle nucleotide polymorphismBiology (General)QH301-705.5ENOpen Life Sciences, Vol 16, Iss 1, Pp 142-149 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	abcb1 p-glycoprotein clopidogrel single nucleotide polymorphism Biology (General) QH301-705.5
spellingShingle	abcb1 p-glycoprotein clopidogrel single nucleotide polymorphism Biology (General) QH301-705.5 Mugosa Snezana Todorovic Zoran Cukic Jelena Sahman-Zaimovic Majda Djordjevic Natasa ABCB1 polymorphism in clopidogrel-treated Montenegrin patients
description	Clopidogrel is an antiplatelet drug that displays significant interindividual variability in treatment response. Its bioavailability depends on the function of P-glycoprotein (P-gp), which is coded by a highly polymorphic ABCB1 gene. Thus, the aim of this study was to investigate the effect of ABCB1 genetic polymorphism on clopidogrel efficacy and safety and to determine the frequency distribution of its most common single nucleotide polymorphisms (SNPs) in 106 Montenegrin cardiology patients. Clopidogrel efficacy and safety were followed up during 1 year after hospitalization, with the lack of efficacy and adverse drug reactions observed in 11 (10.4%) and 8 patients (7.5%), respectively. Genotyping for ABCB1 SNPs rs1128503 (1236C > T), rs2032582 (2677G > A/T), and rs1045642 (3435C > T) was performed by the real-time PCR method, and the variant alleles were detected with the frequencies of 42.9, 44.8, and 52.8%, respectively. No significant association was observed between any of the examined genotypes and clopidogrel efficacy (p = 0.253) or safety (p = 0.424). Due to small sample size, co-treatment with other drugs, and other genetic factors not taken into account, we believe the absence of correlation between ABCB1 genotypes and indicators of clopidogrel efficacy and safety in this study should be apprehended conditionally, and that larger and better-controlled studies are warranted.
format	article
author	Mugosa Snezana Todorovic Zoran Cukic Jelena Sahman-Zaimovic Majda Djordjevic Natasa
author_facet	Mugosa Snezana Todorovic Zoran Cukic Jelena Sahman-Zaimovic Majda Djordjevic Natasa
author_sort	Mugosa Snezana
title	ABCB1 polymorphism in clopidogrel-treated Montenegrin patients
title_short	ABCB1 polymorphism in clopidogrel-treated Montenegrin patients
title_full	ABCB1 polymorphism in clopidogrel-treated Montenegrin patients
title_fullStr	ABCB1 polymorphism in clopidogrel-treated Montenegrin patients
title_full_unstemmed	ABCB1 polymorphism in clopidogrel-treated Montenegrin patients
title_sort	abcb1 polymorphism in clopidogrel-treated montenegrin patients
publisher	De Gruyter
publishDate	2021
url	https://doaj.org/article/18aa7aa0caa3424b824c163bf3689988
work_keys_str_mv	AT mugosasnezana abcb1polymorphisminclopidogreltreatedmontenegrinpatients AT todoroviczoran abcb1polymorphisminclopidogreltreatedmontenegrinpatients AT cukicjelena abcb1polymorphisminclopidogreltreatedmontenegrinpatients AT sahmanzaimovicmajda abcb1polymorphisminclopidogreltreatedmontenegrinpatients AT djordjevicnatasa abcb1polymorphisminclopidogreltreatedmontenegrinpatients
_version_	1718371825703976960

ABCB1 polymorphism in clopidogrel-treated Montenegrin patients

Ejemplares similares